Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma

Clinical trial NCT04604028 · UNKNOWN

Trial details

NCT number: NCT04604028
Sponsor: National Taiwan University Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Antibiotics-unresponsive MALT Lymphoma Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT)

Start date: 2020-11-10
Primary completion: 2022-12-31
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.